Kidney Cancer

>

Latest News

Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.
Stereotactic Radiation Appears Effective in Primary Renal Cell Cancer

March 20th 2024

Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.

Practices should not differentiate treatment options based on race for patients with metastatic renal cell carcinoma, according to Jasmeet Kaur, MD.
Comparable Findings in White and Black Populations for ICI Use in Metastatic RCC

February 20th 2024

Belzutifan Improves QoL and Disease Progression Time in Advanced Kidney Cancer
Belzutifan Improves QoL and Disease Progression Time in Advanced Kidney Cancer

January 27th 2024

Subcutaneous Nivolumab Demonstrates Noninferiority to Standard IV Dosing in ccRCC
Subcutaneous Nivolumab Demonstrates Noninferiority to Standard IV Dosing in ccRCC

January 27th 2024

Adjuvant Pembrolizumab Shows Statistical Improvement in Survival in ccRCC
Adjuvant Pembrolizumab Shows Statistical Improvement in Survival in ccRCC

January 27th 2024

Latest CME Events & Activities

What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations

View More

Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond

View More

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

View More

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News